YANTAI DONGCHENG PHARMACEUTICAL GROUP CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.36 CNY | -3.29% |
|
-7.76% | -32.57% |
| Apr. 11 | Dongcheng Biochemicals' Unit Gets Nod to Trial Tumor Drug in Singapore | MT |
| Feb. 21 | Dongcheng Pharmaceutical to Buy Liver Drug Rights from Affiliate for 85 Million Yuan | MT |
| Sales 2023 * | 3.51B 484M | Sales 2024 * | 3.85B 532M | Capitalization | 10.19B 1.41B |
|---|---|---|---|---|---|
| Net income 2023 * | 373M 51.52M | Net income 2024 * | 460M 63.53M | EV / Sales 2023 * | 2.91 x |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 2.65 x |
| P/E ratio 2023 * |
27.3
x | P/E ratio 2024 * |
22.1
x | Employees | 2,174 |
| Yield 2023 * |
1.21% | Yield 2024 * |
0.61% | Free-Float | 63.12% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.29% | ||
| 1 week | -7.76% | ||
| Current month | -9.52% | ||
| 1 month | -21.97% | ||
| 3 months | -27.68% | ||
| 6 months | -29.17% | ||
| Current year | -32.57% |
1 week
12.11
13.28
1 month
12.1116.46
Current year
12.0519.08
1 year
12.0520.15
3 years
9.9422.98
5 years
9.9429.60
10 years
5.3429.60
| Managers | Title | Age | Since |
|---|---|---|---|
Zhi Gang Luo
CEO | Chief Executive Officer | 53 | 18-08-09 |
Qing Lin Liu
CHM | Chairman | 53 | 98-12-30 |
Chun Ping Zhu
DFI | Director of Finance/CFO | 59 | 98-12-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shou Yi You
CHM | Chairman | 62 | 07-12-18 |
Xiao Jie Liu
BRD | Director/Board Member | 42 | 18-01-22 |
Chun Xiang Lue
PRN | Corporate Officer/Principal | 49 | 98-12-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 117 M€ | -1.36% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 12.36 | -3.29% | 19 014 700 |
| 24-04-18 | 12.78 | -0.16% | 13,356,150 |
| 24-04-17 | 12.8 | +0.95% | 12,607,290 |
| 24-04-16 | 12.68 | -2.91% | 9,763,362 |
| 24-04-15 | 13.06 | -0.91% | 8,711,300 |
End-of-day quote Shenzhen S.E., April 18, 2024
More quotes
Yantai Dongcheng Biochemicals Co., Ltd is a China-based company principally engaged in the research, development, manufacture and sales of medical drugs. The Companyâs main products are categorized into active pharmaceutical ingredients (APIs), nuclear medicines, chemical drugs and traditional Chinese medicines, which include heparin sodium APIs, chondroitin sulfate, preparation products, radionuclide drugs and others. The Company distributes its products in domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-04-26
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
12.78
CNY
Average target price
20.3
CNY
Spread / Average Target
+58.84%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -32.57% | 1.46B | |
| +20.91% | 43.54B | |
| +16.96% | 21.74B | |
| +9.05% | 13.53B | |
| +7.98% | 13.02B | |
| +33.80% | 11.28B | |
| -11.05% | 6.99B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +7.71% | 5.09B |
- Stock Market
- Equities
- 002675 Stock
